Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKarun NeupaneCWCorbin WrightJWJunmin Whiting

Discussion

Loading...

Member takes

Overview

Retrospective study reveals 79% overall response rate for talquetamab in multiple myeloma, suggesting need for tailored therapy.

Key Points

  • This study evaluates the real-world outcomes and prognostic factors for patients with relapsed/refractory multiple myeloma treated with talquetamab.
  • Single center retrospective study of 87 RRMM patients treated with talquetamab at Moffitt Cancer Center.
  • Responses assessed by IMWG criteria; toxicities evaluated per ASTCT consensus and MRD by next-generation sequencing.
  • Overall survival and progression free survival were estimated using Kaplan-Meier and Cox regression methods.
  • Overall response rate was 79%, with 72% achieving response by day 30.
  • Median progression-free survival was 8.4 months, while median overall survival was not reached.
  • High-risk cytogenetics and prior BsAb exposure were associated with inferior outcomes.

Cite This Study

Neupane et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da94https://doi.org/10.1182/blood-2025-4051
View Full Paper
Ask AI
Bookmark
Share